11 – 20 of 26
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2021
-
Mark
Targeted genomic investigations in a population-based cohort of mantle cell lymphoma reveal novel clinically relevant targets
- Contribution to journal › Article
- 2020
-
Mark
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
- Contribution to journal › Article
- 2019
-
Mark
Ibrutinib inhibits antibody dependent cellular cytotoxicity induced by rituximab or obinutuzumab in MCL cell lines, not overcome by addition of lenalidomide
- Contribution to journal › Article
-
Mark
Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study
(2019) In British Journal of Haematology
- Contribution to journal › Article
- 2018
-
Mark
Mantle cell lymphoma strategies in primary treatment
- Thesis › Doctoral thesis (compilation)
-
Mark
Treatment for patients with relapsed/refractory mantle cell lymphoma : European-based recommendations
- Contribution to journal › Article
- 2017
-
Mark
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
- Contribution to journal › Article
-
Mark
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus
- Contribution to journal › Article
- 2016
-
Mark
A Molecular Dissection of Mantle Cell Lymphoma - From gene expression analysis to functional evaluation of selected targets
(2016)
- Thesis › Doctoral thesis (compilation)
-
Mark
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2) : Prolonged remissions without survival plateau
- Contribution to journal › Article
